ItalyItaly

'Growth’ in the midst of crisis

12.06.2011

Milan – Everyone agrees that Italy is not Greece, but it is common wisdom that the country could also be doing better. Considering the meagre growth of the Italian economy in the last decade however, data fom the 2011 survey of the country’s biotech industry should be viewed in a positive light. To start with – there are more and more firms. 221 biotech companies were counted in 2010 (2009: 215), while 2,250 staff work in mostly tiny firms. Revenues are not negligible. Italy generated EUR1.2bn in biotech turnover last year, of which 45% was ploughed back into research. “Biotechnology has become a solid industrial reality in all application areas,” said Alessandro Sidoli, President of Assobiotec. The industry outfit commissions the country’s yearly report together with Ernst & Young. This year, Sidoli’s association is celebrating its 25th birthday, and is especially eager to show that biotech is one of the all-too-few economic success stories in Italy. Even assuming absolute numbers are deceptive – nearly every country counts companies, revenues and other key indicators in different ways – it is clear that in Italy, the sector is growing and providing high-level jobs. A parallel to other countries is the prevalence of red biotech. 185 dedicated companies are operating in the field. And although an Italian bio­pharmaceutical has yet to reach market, there is a notable pipeline: 64 products are in pre-clinical testing there, with 21 in Phase I, 26 in Phase II and 13 in Phase III. Rare diseases are a speciality. Last year saw a 10% increase in the number of Italian Orphan Drug Designations obtained by European and US regulatory authorities, even though just 1.2% of Italy’s GDP was invested in research in 2010 and the percentage of government researchers dropped from 19.9% in 2003 to 16.9%, according to OECD figures. Italian researchers are holding out, and in areas like cancer or neurodegenerative diseases they still are globally competitive. The elephant in the room in Italian bio­technology remains the absence of capital. Ernst & Young cites investments of just a72m in 2010 – with VC, private equity and IPOs counted together. That’s an increase of 27% compared to 2009, but still embarrassingly small for a large economy. And the tide doesn’t seem to be turning in 2011. With the postponed IPO of cancer specialist Philogen in February, Italy’s red biotech scene has to produce a major news announcement this year.

Politics / Law

23.03.2012

Brussels/Strasbourg – Health claims are set to be drastically limited in the EU. On Wednesday 21 March the Environment Committee of the European Parliament confirmed a proposal of the European Commission to prohibit 1,600 health...

Politics / Law

15.03.2012

Parma/Stockholm – Foodborne bacteria such as Salmonella and Campylobacter are becoming more and more resistant to antimicrobial drugs, according to a joint report published by the European food watchdog EFSA and the European...

BioFunding

09.03.2012

In mid-February, scientists and entrepreneurs from nine EU countries met at the Center for Genomic Regulation (CRG) in Barcelona to launch the 4DCellFate project. Positioned within the FP7 Programme, the consortium will receive...

BioFunding

09.03.2012

Brussels – The EU’s Innovative Medicines Initiative (IMI) will establish the European Lead Factory, an EU-wide public-private partnership aiming to facilitate drug discovery efforts. The Lead Factory will comprise a...

Editorial

07.03.2012

T    he societal and economic challenges facing Europe and the world are complex and interconnected. The Bioeconomy Strategy and Action Plan “Innovating for Sustainable Growth: a Bioeconomy for Europe”, which was adopted by the...

Tech Review

07.03.2012

Intellectual Property (IP) is without question one of the most vital aspects of any bio­tech venture, a key and undisputed factor for success. However, most bio­tech companies are still incapable of unlocking the value of their...

Clinical Trial

07.03.2012

Schlieren – Swiss Cytos Biotechnology Ltd. has been authorised to restructure a convertible bond by Canton of Zurich authorities. The company does not have enough cash to pay it back. Negotiations with bond holders failed in a...

Clinical Trial

06.03.2012

Munich – German 4SC AG jumped 39% to €2.05/share after oncology drug candidate resminostat met the primary endpoint of at least a 20% progression-free survival rate in a Phase II trial to treat patients with hepatocellular...

Editorial

06.03.2012

The start of 2012 witnessed the tides turning in favour of small and mid-cap names in the European Life Sciences sector. Major global biotechnology indices like the NBI, BTK, and BIOTK are up over 15% year to date. The pace of...

Displaying results 1 to 10 out of 1983

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive/article/growth-in-the-midst-of-crisis.html

Product of the week

Products

Events

All Events

Current issue

All issues